| Long name: |
FRAT2 Primary Polyclonal Antibody |
| Also known as: |
FRAT2 PAb |
| Category: |
Primary Antibodies |
| Conjugation: |
Unconjugated |
| Target Antigen: |
FRAT2 |
| Specificity: |
This is a highly specific antibody against FRAT2 |
| Modification(s): |
None |
| Modification site(s): |
Unmodified antibody |
| Clonality: |
Polyclonal antibody |
| Clone number: |
Polyclonal antibody |
| Concentration: |
1ug per 1ul |
| Source: |
This antibody was obtained by immunization of the host with KLH conjugated synthetic peptide derived from human FRAT2 |
| Gene ID number: |
23401 |
| Tested Applications: |
IF(IHC-P), IHC-P, WB |
| Recommended dilutions: |
IF(IHC-P)(1:50-200), IHC-P(1:100-500), WB(1:100-1000) |
| Cross reactivity: |
Mouse, Rat, Human |
| Cross reactive species details: |
not every possible cross-reactivity is known, Due to limited amount of testing and knowledge |
| Background of the target antigen: |
Establishment of these embryonic axes is mediated by the Wnt intracellular signaling pathway, FRAT2 has been shown to bind xGSK-3, GBP binds to GSK-3 and inhibits this phosphorylation, Like GBP, These proteins share significant homology with the Xenopus glycogen synthase kinase-3 (xGSK-3) binding protein, Wnt signaling is regulated in part by the activity of GSK-3, and they have since been identified as proto-oncogenes involved in tumorigenesis, resulting in the accumulation of ?catenin and the subsequent transcription of Wnt target genes, suggesting that FRAT1 and FRAT2 may be GSK-3 regulatory proteins, which is designated GBP and is essential for the formation of the dorsal-ventral axis during embryonic development, which phosphorylates and thereby facilitates the degradation of ?catenin, FRAT1 and FRAT2 were originally characterized as proteins frequently rearranged in advanced T cell lymphoma |
| Purification method: |
This antibody was purified via Protein A |
| Storage conditions: |
50% glycerol and 0, Store at -20°, 09% sodium azide, C for up to 1 year, Keep the antibody in aqueous buffered solution containing 1% BSA |
| Synonym names: |
FRAT2_HUMAN, Frequently rearranged in advanced T-cell lymphomas 2 antibodyGSK-3 binding protein FRAT2 |
| Properties: |
C, C for long term storage and for short term at + 5°, If you buy Antibodies supplied by Bioss Primary Unconjugated Antibodies they should be stored frozen at - 24° |
| Gene target: |
FRAT2 |
| Short name: |
FRAT2 Antibody |
| Technique: |
antibodies against human proteins, antibodies for, Antibody |
| Alternative name: |
frequently rearranged in advanced T-cellular lymphomas 2 (Antibody to) |
| Alternative technique: |
antibodies |
| Alternative to gene target: |
FRAT2 and IDBG-648820 and ENSBTAG00000046701 and 539144, FRAT2 and IDBG-84538 and ENSG00000181274 and 23401, Frat2 and IDBG-166307 and ENSMUSG00000047604 and 212398, molecular_function, multiple, this GO :0003674 and molecular function and molecular function this GO :0005575 and cellular component and cellular component this GO :0007275 and multicellular organismal development and biological process this GO :0008283 and cell proliferation and biological process this GO :0016055 and Wnt signaling pathway and biological process, this GO :0003674 : molecular_function, this GO :0003674 : molecular_function, frequently rearranged in advanced T-cell lymphomas 2 |
| Identity: |
16048 |
| Gene: |
FRAT2 |
More about : FRAT2 |
| Long gene name: |
FRAT2, WNT signaling pathway regulator |
| Synonyms gene name: |
frequently rearranged in advanced T-cell lymphomas 2 |
| Synonyms name: |
GSK-3 binding protein FRAT2 |
| Locus: |
10q24, 1 |
| Discovery year: |
2001-07-06 |
| GenBank acession: |
AF062739 |
| Entrez gene record: |
23401 |
| Pubmed identfication: |
9635432 11237732 |
| RefSeq identity: |
NM_012083 |
| Havana BLAST/BLAT: |
OTTHUMG00000018850 |